Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

A. The Assessment Reports for this appraisal were prepared by:

I) Southampton Health Technology Assessment Centre, University of Southampton

  • Clinical and cost effectiveness of growth hormone in adults: Quality of life, October 2001

II) School of Health and Related Research (ScHARR), University of Sheffield

  • Clinical and cost effectiveness of recombinant human growth hormone (somatropin) in adults, April 2002

  • Response to comments received from consultees responding to the post appeal considerations for the clinical and cost effectiveness of recombinant human growth hormone (somatropin) in adults, January 2003

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Reports, and Appraisal Consultation Document (ACD). Consultee organisations were provided with the opportunity to appeal against the Final Appraisal Determination (FAD).

I) Manufacturer/sponsors:

  • Eli Lilly

  • Novo Nordisk

  • Pharmacia

II) Professional/specialist and patient/carer groups:

  • British Society for Paediatric Endocrinology and Diabetes

  • Department of Diabetes, Endocrinology and General Medicine, The Guy's, King's College and St Thomas' Hospitals Medical and Dental School

  • Department of Health & Welsh Assembly Government

  • NHS Quality Improvement Scotland

  • Pituitary Foundation

  • Restricted Growth Association

  • Royal College of Paediatrics and Child Health

  • Royal College of Physicians

  • Society for Endocrinology

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on human growth hormone (somatropin) in adults with growth hormone deficiency by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Gary Butler, Consultant Paediatric and Adolescent Endocrinologist, Leeds General Infirmary

  • Dr Charles R Buchanan, Consultant Paediatric Endocrinologist, King's College Hospital, London

  • Dr Janet Harbour, Pituitary Foundation

  • Ms Patsy Perrin, Vice-Chair, Pituitary Foundation

  • Professor D G Johnston, Department of Endocrinology and Metabolic Medicine, Imperial College School of Medicine and St Mary's Hospital

  • Professor John Monson, Consultant in Endocrinology, St Bartholomew's Hospital, London

  • Professor John Wass, Chair of Clinical Committee, Society for Endocrinology

  • Professor M C Sheppard, Professor of Medicine and Head of Division, Queen Elizabeth Hospital, Birmingham

  • Professor Paul Stewart, Consultant Endocrinologist, Queens Medical Centre, Birmingham

  • Professor Richard Ross, Professor of Endocrinology, Northern General Hospital, Sheffield

  • Professor Steven Shalet, Consultant Endocrinologist, Christie Hospital, Manchester

  • Sue Thorn, Honorary Secretary, Pituitary Foundation